Table 3.

Antibiotics resistance trends in 2015–2019 (a) and 2020–2022 (b). Statistically significant values are indicated in bold.

(a)
Antibiotics	2015		2016		2017		2018		2019		Total Years		p-Value	p-Value Trend
	R	N. Test	R	N. Test	R	N. Test	R	N. Test	R	N. Test	R	N. Test
Pip./taz.	43.2%	285	42.2%	332	25.5%	196	34.2%	357	39.1%	445	37.7%	1615	0.001	0.11
Ceftazidime	38.0%	292	33.7%	344	43.1%	283	29.9%	365	30.8%	448	34.4%	1732	0.01	0.126
Cefepime	29.4%	293	26.7%	345	31.0%	287	26.4%	307	28.6%	147	28.3%	1379	0.69	0.794
Imipenem	34.6%	286	39.0%	341	39.0%	282	29.4%	306	26.6%	143	34.6%	1358	0.02	0.0221
Amikacin	17.2%	285	20.4%	319	25.3%	273	12.4%	354	13.5%	415	17.2%	1646	<0.0001	0.089
Gentamicin	28.8%	292	24.5%	343	32.4%	284	20.0%	365	23.2%	449	25.2%	1733	0.00	0.0326
Ciprofloxacin	44.0%	291	39.5%	344	47.2%	284	37.8%	365	44.2%	450	42.4%	1734	0.09	0.931
Levofloxacin	53.3%	15	53.3%	30	52.9%	34	62.1%	29	40.7%	54	50.6%	162	0.01	0.312
(b)
Antibiotics	2020			2021			2022			Total Years			p-Value	p-Value Trend
	I	R	N. Test	I	R	N. Test	I	R	N. Test	I	R	N. Test
Pip./taz.	11.7%	40.1%	349	43.4%	40.2%	468	60.2%	39.2%	475	41.0%	39.8%	1292	0.0188	0.017
Ceftazidime	13.2%	34.3%	356	53.0%	30.0%	474	66.4%	35.3%	467	46.9%	33.1%	1297	0.0497	0.0143
Cefepime	9.7%	27.8%	299	55.5%	24.7%	474	70.3%	28.5%	478	50.2%	26.9%	1251	0.00249	<0.001
Imipenem	5.7%	30.3%	300	48.6%	32.8%	475	66.3%	33.7%	478	45.1%	32.6%	1253	<0.001	<0.001
Amikacin	1.5%	13.3%	332	0.4%	10.7%	466	0.0%	11.6%	476	0.5%	11.7%	1274	0.553	0.278
Tobramycin	0%	21.4%	248	0.0%	17.4%	380	0.0%	24.4%	401	0.0%	21.1%	1029	<0.001	<0.001
Ciprofloxacin	13.2%	41.6%	356	48.7%	36.1%	474	60.5%	39.1%	478	43.3%	38.7%	1308	0.124	0.0422

Pip./taz., piperacillin/tazobactam.